675112-70-6

Basic information

• Product Name: 4,4-Difluorocyclohexanamine hydrochloride
• Synonyms: Cyclohexanamine,4,4-difluoro-, hydrochloride (9CI);(4,4-Difluorocyclohexyl)aminehydrochloride;(4,4-Difluorocyclohexyl)ammonium chloride;Cyclohexanamine,4,4-difluoro-, hydrochloride (1:1);1-Amino-4,4-difluorocyclohexane hydrochloride;4,4-Difluorocyclohexylamine HCl
• CAS NO: 675112-70-6
• Molecular Formula: C₆H₁₁F₂N*ClH
• Molecular Weight: 171.616
• Product Categories: Amines
• Mol File: 675112-70-6.mol

Chemical Properties

• Melting Point: 295°C
• Boiling Point: 45-47 ºC/12mm
• Flash Point: 67.4oC
• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4,4-Difluorocyclohexanamine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4-Difluorocyclohexanamine hydrochloride(675112-70-6)
• EPA Substance Registry System: 4,4-Difluorocyclohexanamine hydrochloride(675112-70-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 675112-70-6(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 675112-70-6 differently. You can refer to the following data:
1. Cyclohexyl-substituted pyrrolidinones
2. Cyclohexyl-substituted pyrrolidinones and their use as inhibitors of 11-β-hydroxysteroid dehydrogenase 1.

InChI:InChI=1/C6H11F2N.ClH/c7-6(8)3-1-5(9)2-4-6;/h5H,1-4,9H2;1H

Upstream product

• 675112-67-1 tert-butyl (4,4-difluorocyclohexyl)carbamate 
• 675112-69-3 tert-butyl (4-fluorocyclohex-3-en-1-yl)carbamate 
• 224309-64-2 tert-butyl N-(4-hydroxycyclohexyl)carbamate 
• 179321-49-4 N-(tert-butoxycarbonyl)-4-aminocyclohexanone 

Downstream Products

• 956382-42-6 4-chloro-N-(4,4-difluoro-cyclohexyl)-butyramide 
• 1087350-58-0 6-{5-[(4,4-difluorocyclohexylamino)methyl]naphthalen-1-yloxy}-nicotinamide 
• 1000698-98-5 1,1-difluoro-4-isocyanocyclohexane 
• 956223-39-5 (R)-3-(4-benzyloxy-2,6-dichloro-benzyl)-1-(4,4-difluoro-cyclohexyl)-pyrrolidin-2-one 

Relevant articles and documents

Iridinesulfonamide compound and use method thereof

An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically-acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation-induced cancers.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: having 11β -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.

PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS

The invention relates to a compound of formula (I) or a salt thereof: wherein:R1 is C1-4alkyl, C1-3fluoroalkyl, -CH2CH2OH or -CH2CH2CO2C1-2alkyl;R2 is a hydrogen atom (H), methyl or C1fluoroalkyl;R3 is optionally substituted C3-8cycloalkyl or optionally substituted mono-unsaturated-C5-7cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc); in which n1 and n2 independently are 1 or 2; and in which Y is O, S, SO2, or NR10; or R3 is a bicyclic group (dd) or (ee): ; and wherein X is NR4R5 or OR5a. The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.